Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver.

Vera-Aguilera J, Bedikian AY, Bassett RL, Hwu WJ, Kim KB, Qin Y, Cain S, Washington EW, Davies MA, Patel SM, Homsi J, Papadopoulos NE, Hwu P, Patel SP.

Am J Clin Oncol. 2018 Mar 5. doi: 10.1097/COC.0000000000000436. [Epub ahead of print]

PMID:
29509591
2.

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.

Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY.

Cancer Immunol Immunother. 2017 Oct;66(10):1359-1366. doi: 10.1007/s00262-017-2030-y. Epub 2017 Jun 13.

PMID:
28612140
3.

A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.

McQuade JL, Posada LP, Lecagoonporn S, Cain S, Bassett RL Jr, Patel SP, Hwu WJ, Hwu P, Davies MA, Bedikian AY, Amaria RN.

Melanoma Res. 2016 Dec;26(6):604-608.

4.

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.

Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R.

Oncotarget. 2015 Sep 15;6(27):24581.

5.

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.

Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R.

Oncotarget. 2015 May 20;6(14):12809-21. Erratum in: Oncotarget. 2015 Sep 15;6(27):24581.

6.

Metastasis of ciliary body melanoma to the contralateral eye: a case report and review of uveal melanoma literature.

Torossian NM, Wallace RT, Hwu WJ, Bedikian AY.

Case Rep Oncol Med. 2015;2015:427163. doi: 10.1155/2015/427163. Epub 2015 Mar 22.

7.

Uveal melanoma in the first 4 decades of life.

Sagus M, Bedikian AY.

South Med J. 2015 Mar;108(3):158-63. doi: 10.14423/SMJ.0000000000000248.

PMID:
25772049
8.

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.

Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA.

J Invest Dermatol. 2015 Feb;135(2):508-515. doi: 10.1038/jid.2014.366. Epub 2014 Aug 22.

9.

Malignant melanoma in teenagers and young adults.

Kolandijan NA, Wei C, Burke A, Bedikian AY.

J Pediatr Hematol Oncol. 2014 Oct;36(7):552-8. doi: 10.1097/MPH.0000000000000231.

PMID:
25089601
10.

A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.

Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Rojas PB, Schwartz JD, Bedikian AY.

Eur J Cancer. 2014 Aug;50(12):2099-107. doi: 10.1016/j.ejca.2014.03.289. Epub 2014 Jun 12.

11.

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.

Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R Jr, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P.

Melanoma Res. 2014 Aug;24(4):342-8. doi: 10.1097/CMR.0000000000000062.

12.

Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.

Bedikian AY, Garbe C, Conry R, Lebbe C, Grob JJ; Genasense Melanoma Study Group.

Melanoma Res. 2014 Jun;24(3):237-43. doi: 10.1097/CMR.0000000000000056.

PMID:
24667300
13.

High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.

Deitcher OR, Glaspy J, Gonzalez R, Sato T, Bedikian AY, Segarini K, Silverman J, Deitcher SR.

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):197-202. doi: 10.1016/j.clml.2013.10.012. Epub 2013 Nov 15.

PMID:
24417913
14.

Surveillance for brain metastases in patients receiving systemic therapy for advanced melanoma.

Wang J, Wei C, Noor R, Burke A, McIntyre S, Bedikian AY.

Melanoma Res. 2014 Feb;24(1):54-60. doi: 10.1097/CMR.0000000000000022.

PMID:
24121189
15.

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.

Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM.

Invest New Drugs. 2014 Apr;32(2):279-86. doi: 10.1007/s10637-013-9966-3. Epub 2013 Jun 12.

17.

Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.

Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P.

J Immunother. 2013 May;36(4):276-86. doi: 10.1097/CJI.0b013e31829419f3.

18.

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P.

Clin Cancer Res. 2012 Dec 15;18(24):6758-70. doi: 10.1158/1078-0432.CCR-12-1177. Epub 2012 Oct 2.

19.

BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.

Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB.

J Cutan Pathol. 2012 Sep;39(9):821-5. doi: 10.1111/j.1600-0560.2012.01950.x. Epub 2012 Jul 19.

20.

Delayed systemic recurrence of uveal melanoma.

Kolandjian NA, Wei C, Patel SP, Richard JL, Dett T, Papadopoulos NE, Bedikian AY.

Am J Clin Oncol. 2013 Oct;36(5):443-9. doi: 10.1097/COC.0b013e3182546a6b.

21.

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckeweg A, Colevas AD.

Melanoma Res. 2012 Aug;22(4):294-301. doi: 10.1097/CMR.0b013e32835312e4.

22.

Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases.

Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA.

Melanoma Res. 2012 Aug;22(4):310-5. doi: 10.1097/CMR.0b013e328353efd8.

23.

Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.

Noor R, Bedikian AY, Mahoney S, Bassett R Jr, Kim K, Papadopoulos N, Hwu WJ, Hwu P, Homsi J.

Support Care Cancer. 2012 Oct;20(10):2583-8. doi: 10.1007/s00520-011-1359-6. Epub 2012 Jan 25.

PMID:
22274951
24.

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.

Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB.

Clin Cancer Res. 2012 Feb 15;18(4):1120-8. doi: 10.1158/1078-0432.CCR-11-2436. Epub 2012 Jan 5.

25.

A phase II study of gefitinib in patients with metastatic melanoma.

Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY.

Melanoma Res. 2011 Aug;21(4):357-63. doi: 10.1097/CMR.0b013e3283471073.

26.

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.

Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG.

Clin Cancer Res. 2011 Jul 15;17(14):4882-91. doi: 10.1158/1078-0432.CCR-10-2769. Epub 2011 Jun 1.

27.

The left ventricle as the first site of uveal melanoma metastasis 13 years after treatment of the primary tumor.

Kolandjian NA, Patel SP, Papadopoulos NE, Bedikian AY.

Melanoma Res. 2011 Apr;21(2):160-3. doi: 10.1097/CMR.0b013e328344958c.

PMID:
21346640
28.

Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck.

Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB.

Melanoma Res. 2011 Apr;21(2):127-30. doi: 10.1097/CMR.0b013e3283426821.

PMID:
21169870
29.

Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma.

Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY.

Cancer Invest. 2011 Jan;29(1):49-55. doi: 10.3109/07357907.2010.535052.

PMID:
21166498
30.

Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.

Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P.

Am J Clin Oncol. 2011 Dec;34(6):603-10. doi: 10.1097/COC.0b013e3181f9456a.

PMID:
21150567
31.

Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P.

Melanoma Res. 2011 Feb;21(1):84-90. doi: 10.1097/CMR.0b013e328341445f. Review.

PMID:
21102360
32.

Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.

Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P.

J Clin Pharmacol. 2011 Aug;51(8):1205-12. doi: 10.1177/0091270010381499. Epub 2010 Oct 26.

PMID:
20978276
33.

Prognostic factors for survival in melanoma patients with brain metastases.

Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A.

Cancer. 2011 Apr 15;117(8):1687-96. doi: 10.1002/cncr.25634. Epub 2010 Oct 19.

34.

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.

Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P.

Melanoma Res. 2010 Dec;20(6):507-10. doi: 10.1097/CMR.0b013e3283403ce9.

PMID:
20881508
35.

Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.

Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A.

Melanoma Res. 2010 Dec;20(6):501-6. doi: 10.1097/CMR.0b013e32833faf18.

PMID:
20859231
36.

Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.

Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, Ernstoff M.

Ann Oncol. 2011 Apr;22(4):787-93. doi: 10.1093/annonc/mdq438. Epub 2010 Sep 20.

37.

A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.

Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R.

Cancer. 2010 Sep 1;116(17):4086-94. doi: 10.1002/cncr.25277.

38.

GPNMB expression in uveal melanoma: a potential for targeted therapy.

Williams MD, Esmaeli B, Soheili A, Simantov R, Gombos DS, Bedikian AY, Hwu P.

Melanoma Res. 2010 Jun;20(3):184-90. doi: 10.1097/CMR.0b013e3283364a08.

PMID:
20375921
39.

A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma.

Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R.

Melanoma Res. 2010 Jun;20(3):218-26. doi: 10.1097/CMR.0b013e3283390711.

PMID:
20354459
40.

Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.

Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1087-93. doi: 10.1007/s00280-010-1266-4. Epub 2010 Mar 4.

41.

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.

Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE.

J Transl Med. 2010 Jan 29;8:9. doi: 10.1186/1479-5876-8-9.

42.

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.

Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, Hammershaimb L, Kirkwood JM; Etaracizumab Melanoma Study Group.

Cancer. 2010 Mar 15;116(6):1526-34. doi: 10.1002/cncr.24821.

43.

The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.

Yoon C, Papadopoulos NE, Camacho LH, McIntyre S, Alvarado GC, Bedikian AY, Hwu P, Kim KB.

Melanoma Res. 2010 Feb;20(1):43-7. doi: 10.1097/CMR.0b013e3283324e2e.

PMID:
19952963
44.

Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors.

Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P.

Am J Clin Oncol. 2010 Oct;33(5):474-80. doi: 10.1097/COC.0b013e3181b4b065.

PMID:
19935383
45.

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.

Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY.

Cancer. 2009 Nov 15;115(22):5228-36. doi: 10.1002/cncr.24576.

46.

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.

Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P.

Melanoma Res. 2009 Aug;19(4):238-42. doi: 10.1097/CMR.0b013e32832a1e2f.

PMID:
19521262
47.

Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.

Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P.

Am J Clin Oncol. 2009 Oct;32(5):509-14. doi: 10.1097/COC.0b013e3181942a1f.

PMID:
19506454
48.

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P.

Cancer Invest. 2009 Aug;27(7):756-63. doi: 10.1080/07357900802709159.

PMID:
19440934
49.

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY.

Melanoma Res. 2009 Feb;19(1):42-9. doi: 10.1097/CMR.0b013e328314b84a.

PMID:
19430405
50.

LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).

Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AM.

Eur J Cancer. 2009 Jul;45(10):1807-14. doi: 10.1016/j.ejca.2009.04.016. Epub 2009 May 4.

PMID:
19419855

Supplemental Content

Loading ...
Support Center